argenx SE (EBR:ARGX)
705.60
-133.00 (-15.86%)
Oct 8, 2026, 5:36 PM CET
argenx SE Revenue
argenx SE had revenue of $1.54B USD in the quarter ending June 30, 2026, with 59.30% growth. This brings the company's revenue in the last twelve months to $5.33B, up 70.59% year-over-year. In the year 2025, argenx SE had annual revenue of $4.25B with 88.63% growth. That makes argenx SE the 2,517th largest company in the world by revenue and 14th in Belgium.
Revenue (ttm)
$5.33B
Revenue Growth
+70.59%
P/S Ratio
11.27
Revenue / Employee
$2.86M
Employees
1,863
Market Cap
44.13B EUR
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 4.25B | 2.00B | 88.63% |
| Dec 31, 2024 | 2.25B | 983.45M | 77.52% |
| Dec 31, 2023 | 1.27B | 823.33M | 184.91% |
| Dec 31, 2022 | 445.27M | -94.15M | -17.45% |
| Dec 31, 2021 | 539.42M | 474.51M | 731.01% |
| Dec 31, 2020 | 64.91M | -29.11M | -30.96% |
| Dec 31, 2019 | 94.03M | 60.43M | 179.91% |
| Dec 31, 2018 | 33.59M | 27.09M | 416.32% |
| Dec 31, 2014 | 6.51M | -719.25K | -9.95% |
| Dec 31, 2013 | 7.23M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| UCB SA | 8.52B |
| European Medical Solutions | 51.36M |
| Hyloris Pharmaceuticals | 9.83M |
| Onward Medical | 8.42M |
| Oxurion NV | 1.15M |
| Financière de Tubize | 13.26K |
| Celyad Oncology | 7.00K |
| BioSenic | -2.39M |
argenx SE News
- 1 hour ago - Argenx has ‘good news and bad news’ day, says H.C. Wainwright - TheFly
- 2 hours ago - Argenx falls -12.4% - TheFly
- 4 hours ago - Argenx discontinues Vyvgart study in Sjögren's disease, shares tumble - Reuters
- 5 hours ago - Argenx Shares Plunge After Autoimmune-Disease Trial Halt - WSJ
- 6 hours ago - Argenx to discontinue UNITY study of efgartigimod subcutaneous - TheFly
- 6 hours ago - Argenx announces FB102 study met its primary endpoint - TheFly
- 11 hours ago - argenx Provides Update on Phase 3 UNITY Study of Efgartigimod SC in Sjögren's Disease - GlobeNewsWire
- 11 hours ago - argenx Announces Positive Topline Results from Phase 2 Study of FB102 in Celiac Disease - GlobeNewsWire